Aspirin use in patients with PIK3CA-mutated colorectal cancer reduces recurrence risk by over 50%. | Drug Discovery And ...

Q4 2024 Management View Brian Sullivan, CEO, highlighted the completion of enrollment for the PIK3CA wild-type cohort in the VIKTORIA-1 Phase III study and the selection of approximately 200 sites for ...

PIK3CA-related overgrowth spectrum (PROS) is a rare genetic disorder that causes uncontrollable growth of parts of the body. Its symptoms vary greatly and affect children physically and emotionally.

Q4 2024 Earnings Call Transcript March 31, 2025 Celcuity Inc. misses on earnings expectations. Reported EPS is $-0.85 EPS, ...

Itovebi, approved for some patients with breast cancer, is the first PI3K inhibitor to display a survival benefit, according ...

That may be because the non-biomarker group in the study included quite a high proportion of untested patients in whom PIK3CA/AKT1/PTEN status was unknown. Mutations in PIK3CA, AKT1, and ...

Celcuity Inc (NASDAQ:CELC) completed enrollment of the PIK3CA wild-type cohort in their VIKTORIA-1 Phase III study, marking significant progress in their clinical development programs. The company ...

The PIK3CA wild-type cohort of the VIKTORIA-1 Phase 3 trial is on track to report topline data in Q2 2025VIKTORIA-2 Phase 3 remains on track to ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

There is no cure for PIK3CA-related overgrowth spectrum, but several options are available to treat the root cause of the condition and help manage symptoms. These include targeted therapy ...

Despite a significant net loss, Celcuity Inc (CELC) advances its clinical trials and maintains a strong cash position to support future growth.